A clinical study by BIOTRONIK to collect data on the safety and efficacy of the 48-mm long drug-eluting Orsiro Mission Stent for the treatment of patients with stenoses in blood vessels in the heart: BIOFLOW-48
Résumé de l'étude
The aim of the study is to collect data on the safety and efficacy of the 48-mm long Orsiro Mission stent. This stent can treat stenotic lesions ranging from 37 mm to 44 mm in length. The international, multicenter clinical study will be conducted at approximately 35 study centers in Europe and the USA, with up to 150 patients to be included. The outcome of the study will be evaluated based on the target lesion failure (TLF) rate after 12 months. TLF is a rate that consists of cardiac death, myocardial infarction (MI) at the treated target vessel (TV), and the target lesion revascularization (TLR) rate.
(BASEC)
Intervention étudiée
Use of the 48-mm long drug-eluting Orsiro Mission Stent in the narrowed section of the coronary artery responsible for the patient's complaints.
(BASEC)
Maladie en cours d'investigation
The coronary arteries (blood vessels in the heart) have a narrowing that may need to be treated. This narrowing can be caused by deposits on the walls of the arteries (atherosclerosis). As a result, the heart is not sufficiently supplied with oxygen and nutrients, which impairs heart function. This disorder is referred to as stenosis of the coronary arteries and can be the cause of clinical symptoms.
(BASEC)
1. Individuals aged >18 years. 2. Written informed consent from the patient. 3. Subjects with a maximum of two lesions in two different coronary arteries, with only one to be treated with the investigational product. (BASEC)
Critères d'exclusion
1. Pregnant or breastfeeding women or women intending to become pregnant during the study. 2. PCI in the target vessel within the last 12 months or PCI in a non-target vessel within the last 72 hours. 3. Target lesion is a complete occlusion. (BASEC)
Lieu de l’étude
Bâle
(BASEC)
Sponsor
BIOTRONIK AG, Bülach CHE
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Doris Lang
+41 75 429 5456
doris.lang@clutterbiotronik.comBIOTONIK AG
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Ethikkommission Nordwest- und Zentralschweiz EKNZ
(BASEC)
Date d'approbation du comité d'éthique
17.03.2025
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
BIOTRONIK – A Prospective Multicenter Single-Arm Study to Assess the Safety and Effectiveness of the Orsiro Mission 48- mm Sirolimus-Eluting Coronary Stent System for the Treatment of Subjects with Atherosclerotic Lesion(s): BIOFLOW-48 (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible